The University of Texas MD Anderson Cancer Center, Invectys Inc., and the Cell Therapy Manufacturing Center, a joint venture between MD Anderson and National Resilience Inc., announced a strategic collaboration to jointly develop a process for human leukocyte antigen-G targeted CAR T-cell therapy for solid tumors.
The University of Texas MD Anderson Cancer Center and Rice University formed the Cancer Bioengineering Collaborative to develop innovative technologies and bioengineering approaches to improve cancer research, diagnosis, and treatment.
